Published
Sources checked through , 5 p.m. Pacific · facts checked and fully reviewed · 2 min read
New Zealand announced on November 12 that Medsafe had approved a generic injectable paliperidone in 25 working days. It was the first product approved under a pathway available when two recognized overseas regulators have already assessed a medicine. New Zealand’s reviewers still verified that the proposed product matched the version assessed abroad and considered local factors. Of three previously authorized brands, the announcement identifies one as funded. A new approval and a new publicly funded dispensing option require different documents. New Zealand Ministry of Health
The European Medicines Agency’s committee for human medicines made seven recommendations on new medicines at its November 9–12 meeting. These included baxdrostat for insufficiently controlled hypertension. It also recommended expanding several existing indications. The committee separately adopted a communication on tirzepatide and oral contraceptives. Readers asking whether a product can be marketed for a new use in the EU should look for the European Commission’s subsequent decision. Readers asking about an existing product’s safety should read the communication and current product information. EMA’s November 13 meeting report
In London on November 17, the UK announced funding to develop and test AdvanceGxP. Its medicines regulator intends to help developers of advanced manufacturing technologies address quality and regulatory questions earlier. The November 18 release identifies AI, robotics and manufacturing closer to patients among the developments challenging conventional production models. Early access to a regulator’s advice leaves the manufacturer responsible for demonstrating that its process consistently delivers the required product quality. The service was in development, with limited initial capacity. MHRA announcement
Australia offers a different example. On November 19 its Therapeutic Goods Administration published guidance on unique device identification. It tells reporters to include an available identifier in adverse-event reports and enter it as text while the system lacks a dedicated field. For a hospital evaluating a software-enabled device, this raises a practical purchasing question. If the device is involved in an incident six months later, can the hospital recover the right identifier from its own records? An invoice identifying only a brand may leave the reviewer unable to establish which device was involved. Australian TGA guidance